Bruker, Serva in Proteomic Reagent Co-Marketing Pact

Bruker Daltonics will co-market and sell a labeling reagent for quantitative proteomics for Serva Electrophoresis of Heidelberg, Germany, the companies said this week.

The technology, called Isotope Coded Protein Label, or ICPL, was developed by researchers at the Max-Planck-Institute of Biochemistry in Martinsried, Germany, and is exclusively licensed to Serva. Under the new agreement, Bruker will provide ICPL kits worldwide.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.